Targeted treatment of prostate cancer

  title={Targeted treatment of prostate cancer},
  author={Xinning Wang and Lihong Yin and Pravin Kumar Rao and Robert J Stein and Kelley M. Harsch and Zhenghong Lee and Warren D. W. Heston},
  journal={Journal of Cellular Biochemistry},
Over a half century ago, Charles Huggins demonstrated the response of prostate cancer to androgen deprivation therapy. Subsequently, many discoveries and evolving findings continued to support a research rationale focused on the androgen receptor (AR) as a key target for prostate cancer. More recently, preliminary trials have suggested that other targets could also be useful in the treatment of prostate cancer, and the proposed strategies for treatment have ranged from targeted toxins to… 

Adenovirus-derived vectors for prostate cancer gene therapy.

The state of the art and future prospects of gene therapy in prostate cancer are reviewed and areas where further developments are necessary are highlighted, with a focus on adenoviral vectors.

Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

It is shown that in addition to blocking cell division, docetaxel impairs AR signaling, evidence that enables new insights into the therapeutic efficacy of microtubule-targeting drugs in prostate cancer.

Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer

The literature on published clinical trials involving therapeutic J591 conjugated to b-emitter, lutetium-177 for mCRPC, is sequentially reviewed.

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives

A brief overview of the current state and the future perspectives of 177Lu labelled PSMA radioligand therapy is given.

Importance of Stromal Stem Cells in Prostate Carcinogenesis Process

The combinatorial use of primary samples, xenografts and cell lines will likely provide the tools for the most rigorous prostate cancer scientists who are studying the complexity of cross-talking between prostatic epithelial cells and stromal stem cells.

The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu‐PSMA therapy

The aim of the present study is to evaluate whether various biochemical markers can predict OS in men undergoing PSMA‐RLT and whether the changes assessed after PSMA-RLT correlate with the OS.

Antibody Recruiting Small Molecules: A New Option for Prostate Tumor Therapy by PSMA Targeting

This approach imitates the basic principle of the authors' native defense mechanism against cancer (and other pathogens): the immune system and can thus be therapeutically useful without the need for conjugation of additional effector molecules.

Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

Overall, a majority of patients responded to therapy, and in the prospective studies, survival was found to be upwards of one year, and patients who had PSA declines in response to therapy had longer survival.

Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.

SNARE-1 inhibits AR function by a mechanism that is distinct from clinically available antiandrogens, such that it might inform novel methods to block AR function in androgen-independent prostate cancer.



Design and Synthesis of a PSMA Inhibitor–Doxorubicin Conjugate for Targeted Prostate Cancer Therapy

The design, synthesis, and biological activity of PSMA–doxorubicin conjugate 1 targeted for prostate cancer therapy are reported, with potential improvements over existing chemotherapy regimens since the drug is delivered preferentially to the cancer tissue and side effects can be minimized.

Recombinant Antibody Candidates for Treatment of Prostate Cancer

This chapter provides an overview of existing monoclonal antibody technology, clinical application, and future direction.

Prostate cancer stem cells

Current evidence for prostate cancer stem cells is focused upon, addressing the identification and properties of both normal and transformed prostate stem cells.

Molecular regulation of androgen action in prostate cancer

This review will examine how recently identified androgen‐regulated genes are likely to contribute to the development and progression of prostate cancer, and summarize several recent studies that have attempted to unravel how these genes are deregulated in androgen depletion independent prostate cancer.

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

  • M. MilowskyD. Nanus N. Bander
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
Acceptable toxicity and excellent targeting of known sites of metastases were demonstrated in patients with multiple solid tumor types, highlighting a potential role for the anti-PSMA antibody J591 as a vascular-targeting agent.

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer

In this review, the regulation of PSMA expression within the cells, and significance of its expression in prostate cancer and metastasis are discussed.

Evolution of the androgen receptor pathway during progression of prostate cancer.

The present work focused on the potential involvement of selective adaptations of the androgen receptor pathway in the initiation and progression of prostate cancer by selecting 200 genes that were androgen responsive in prostate cancer cell lines and/or xenografts, and proposed the following model.

Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.

Prostate stem cells and cancer.

It is proposed that dissemination of rare cancer stem cells may lead to metastatic disease and that resistance of such cells to multiple drugs and androgen ablation make them responsible for failure of current treatments.

A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease.

The observations demonstrate the potential safe and effective intraprostatic application of this engineered protoxin and the safety of PRX302 into the PSA-secreting prostate glands of cynomolgus monkeys, with no toxicity to neighboring organs or general morbidity.